AstraZeneca signs deal to promote product made in China — in mainland China; Israeli deep brain stimulation co Brainsway sets stage for $30M Nasdaq IPO
→ In what is being touted as the first time a multinational pharma company has secured a licence to sell a drug in China developed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
